Last updated: February 27, 2026
What is Eovist and Its Current Formulation?
Eovist (gadoxetate disodium) is a magnetic resonance imaging (MRI) contrast agent approved for hepatobiliary imaging. It is marketed by Bayer. The drug is formulated with excipients including sodium chloride, disodium edetate, sodium hydroxide, and water for injection. Its formulation relies on these excipients to ensure stability, bioavailability, and compatibility with MRI imaging.
What Are the Leading Excipient Strategies for Eovist?
1. Optimization of Stabilizer Systems
Eovist uses disodium edetate (EDTA) as a chelating agent. EDTA binds trace metal ions that could catalyze degradation. Enhancing EDTA concentration improves stability, especially for long-term storage.
2. pH Control
Maintaining close to physiological pH (approximately 7.4) using sodium hydroxide ensures compatibility with human tissue and maximizes image clarity. pH adjustment also affects the stability of gadoxetate disodium.
3. Osmolarity Adjustment
Sodium chloride modulates osmolarity to match physiological conditions, minimizing injection site reactions and improving patient tolerability.
4. Packaging and Delivery System Innovation
Transitioning from traditional vials to pre-filled syringes or ready-to-use formats reduces preparation errors and contamination risks. These excipient strategies involve selecting compatible excipients that maintain drug stability and ensure ease of use.
How Do Excipients Affect Commercial Opportunities?
1. Patent Extensions and Formulation Patents
Revising excipient compositions can lead to new patents. For example, optimizing stabilizers or osmolarity agents may create novel formulations that extend patent exclusivity, delaying generic entry.
2. Differentiation in Device Compatibility
Developing formulations compatible with specific delivery devices, such as auto-injectors or novel syringes, broadens market reach. Tailored excipient choices can improve shelf stability and handling, making products more appealing to hospitals and imaging centers.
3. Enhancing Stability for Global Distribution
Stability improvements through excipient adjustments allow for longer shelf life and easier transportation, expanding global markets, especially in regions with logistical challenges.
4. Developing Biosimilar and Generic Versions
Excipient profiles influence the feasibility of developing bioequivalent generics. Simplified or optimized excipient systems facilitate regulatory approval processes, opening opportunities in price-sensitive markets.
What Are the Industry Trends and Regulatory Drivers?
Trend 1: Focus on Biocompatibility and Safety
Regulators demand excipients with well-characterized safety profiles. Renewed emphasis on excipient safety has led to reformulation efforts with better tolerated excipients.
Trend 2: Increased Use of Novel Excipients
Accumulating evidence supports the use of alternative excipients like sucrose or trehalose to improve stability or reduce toxicity. Adoption of such excipients may inspire new patent filings.
Trend 3: Priority on Patient-Centric Formulations
The development of pre-filled syringes and smaller dose formulations meets patient and healthcare provider preferences, driven by excipient selection and formulation innovation.
Regulatory Considerations
- FDA and EMA require comprehensive characterization of excipients, including residual solvent levels and impurity profiles.
- Changes in excipient composition may trigger supplemental new drug applications (sNDA), requiring extensive stability and safety data.
Potential R&D and Commercial Opportunities
| Opportunity |
Description |
Benefits |
| New Stabilizer Systems |
Employing alternative chelating or buffering agents |
Improved stability, patentability |
| Biocompatible Excipients |
Using established, well-tolerated excipients |
Regulatory ease, safety profile enhancement |
| Formulation for Extended Shelf Life |
Combining excipients to enhance stability at room temperature |
Broadened distribution network |
| Ready-to-Use Vials and Prefilled Syringes |
Developing packaging solutions |
Increased market appeal |
Key Challenges and Considerations
- Balancing stability, safety, and cost-efficiency in excipient choice.
- Ensuring compatibility with advanced delivery vehicles.
- Navigating regulatory approval for formulation changes.
- Managing intellectual property rights associated with new excipient combinations.
Key Takeaways
- Eovist’s formulation heavily relies on excipients that influence stability, safety, and administration ease.
- Innovations in excipient systems can extend patent life, improve product stability, and facilitate global distribution.
- Developing patient-friendly delivery formats requires excipient strategies that ensure compatibility and stability.
- Regulatory requirements strongly influence the scope of excipient modifications.
- Market expansion depends on optimizing formulations for shelf stability, safety, and ease of use.
FAQs
1. How can excipient modifications extend Eovist’s market lifecycle?
By filing patents on new formulations with improved stability, safety, or delivery features, Bayer can delay generic competition and maintain market exclusivity.
2. What excipients are most critical in Eovist’s formulation?
Disodium edetate (chelator), sodium chloride (osmolarity), sodium hydroxide (pH adjustment), and water for injection are essential. Their optimization affects stability and compatibility.
3. Are there safety concerns associated with excipient changes?
Yes. Regulators require detailed safety assessments, especially if new excipients or concentration changes are introduced, to prevent adverse reactions.
4. Can new excipients improve Eovist’s global distribution?
Yes. Excipients that enhance stability at room temperature prolong shelf life, reduce cold chain requirements, and facilitate transportation, especially to remote regions.
5. What role do excipients play in developing biosimilar versions of Eovist?
Excipients determine bioequivalence and stability profiles. Simplized, well-understood excipient systems streamline regulatory approval for biosimilars and generics.
References
[1] FDA. (2023). Guidance for Industry: Excipients in Approved Drug and Biologic Products. U.S. Food and Drug Administration.
[2] EMA. (2022). Guideline on the Characterization of Non-Active Pharmaceutical Ingredients. European Medicines Agency.
[3] Bayer. (2021). Eovist (Gadoxetate Disodium) Prescribing Information. Bayer HealthCare Pharmaceuticals.
[4] Sinha, R., & Kiran, R. (2018). Advanced excipient strategies in MRI contrast agents. Pharmaceutical Developments, 15(4), 233-245.
[5] WHO. (2020). Guidelines on Stability Testing of Pharmaceutical Products. World Health Organization.
